Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Hematologic Cancers

The Hematology Clinic is located on the second floor of The Vanderbilt Clinic and is open from Monday through Friday from 8:00 a.m. to 5:00 p.m. Our physicians see patients with hematologic malignancies, benign hematologic disorders and specialty clinics for sickle cell anemia and hemostasis and thrombosis.

Clinical Trials for Hematologic Cancers

48 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Basic Science

Leukemia

VICCHEM1305

04/02/2013

Investigating Abnormal Signaling in Acute Myeloid Leukemia (AML)

Basic Science

Leukemia

COGAALL08B1

10/18/2010

Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Basic Science

Hematologic

VICCBMT1008

02/18/2010

Skin or Gut Infiltrating Foxp3+ Cells and Their Association with Acute Graft-Versus-Host Disease Severity (deidentified)

Basic Science

Hematologic

NMDPBMT0346

07/09/2003

Repository for National Donor Program (NMDP) Research Blood Samples.

Other

Hematologic

VICCHEM1484

04/22/2015

Prospective, Non-Interventional Study of Disease Progression and Treatment of Patients with Polycythemia Vera in United States Academic or Community Clinical Practices

Other

Myelodysplastic Syndrome

VICCBMT1407

04/17/2015

A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome

Other

Hematologic

VICCBMT1426

11/10/2014

Metabolic and CD4+ T Cell Dysregulation in Post-Transplant Diabetes Mellitus

Other

Hematologic

VICCBMT1401

08/29/2014

Prospective Outcomes of Second-Line Therapy in Acute Graft-versus-Host Study Including ECP (POSTAGE)

Other

Hematologic

VICCBMT1380

02/05/2014

Chronic GVHD Response Measures Validation

Other

Hematologic

VICCBMT1110

11/02/2001

Hematopoietic Stem Cell Transplantaion and Marrow Toxic Injuries (Registry)

Supportive Care

Leukemia
Lymphoma

VICCBMT1501

04/22/2015

A Multicenter OpenLabel Phase 1b/2 Study of Ibrutinib in Steroid Dependent or Refractory Chronic Graft Versus Host Disease

Supportive Care

Leukemia

VICCBMT1427

03/23/2015

A Phase III Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-8228 (Letermovir) for the Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients

Supportive Care

Leukemia

PRECOGHEM0901

12/04/2012

Phase I Dose Finding/Phase II Placebo-Controlled Trial of Eltrombopag During Consolidation Therapy in Adults with Acute Myeloid Leukemia (AML) in Complete Remission

Supportive Care

Leukemia
Pediatric Leukemia

COGACCL0933

11/16/2011

A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)

Treatment

Multiple Myeloma

VICCHEM1509

08/26/2015

An open-label, dose-escalation and multi-center study to evaluate the safety and pharmacokinetics of SAR650984 in patients with relapsed/refractory multiple myeloma

Treatment

Leukemia

VICCHEM1508

08/20/2015

A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 versus Treatment Choice (TC) in Adults with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy

Treatment

Leukemia

VICCHEM1538

07/13/2015

A Phase 1 Dose Escalation and Expansion Study of TGR-1202 + Ruxolitinib in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (PPV-MF), Post-Essential Thrombocythemia MF (PET-MF), MDS/MPN, or Polycythemia Vera Resistant to Hydroxyurea

Treatment

Multiple Myeloma

VICCHEM1526

07/01/2015

A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) plus Low-Dose Dexamethasone in Patients with Multiple Myeloma Quad-refractory to Previous Therapies

Treatment

Leukemia
Lymphoma

VICCBMT1406

06/29/2015

A Multi-Center, Phase III, Randomized Trial of Reduced Intensity(RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (Haplo) for Patients with Hematologic Malignancies

Treatment

Leukemia
Myelodysplastic Syndrome

VICCHEM14135

06/03/2015

A Randomized, Double-Blind Phase 1B/2 Study of PF-04449913 in Combination with AZACITIDINE in Patients with Previously Untreated Intermediate-2 or High-Risk Myelodysplastic Syndrome, Acute Myeloid Leukemia with 20-30% Blasts and Multi-Lineage Dysplasia, or Chronic Myelomonocytic Leukemia.

Treatment

Leukemia

VICCHEM14132

06/03/2015

A Phase 1/2 Study of ABT-199 in Combination with Low-Dose Cytarabine in Treatment-Naive Subjects with Acute Myelogenous Leukemia Who Are ≥ 65 Years of Age and Who Are Not Eligible for Standard Anthracycline-Based Induction Therapy

Treatment

Leukemia
Lymphoma
Pediatric Leukemia
Pediatric Lymphoma

COGAALL1231

05/13/2015

A Phase III Randomized Trial Investigating Bortezomib NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)

Treatment

Leukemia

VICCHEM1505

05/06/2015

An open-label Phase I dose-escalation study to characterize the safety, tolerability, pharmacokinetics, and maximum tolerated dose of BAY 1143572 given in a once-daily or an intermittent dosing schedule in subjects with advanced acute leukemia

Treatment

Lymphoma

VICCHEM1490

04/07/2015

Phase 1/2 Open-label, Multiple-dose, Dose-escalation Study to Evaluate the Safety and Tolerability of IMO-8400 in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma and MyD88 L265P Mutation

Treatment

Lymphoma

VICCHEM1466

03/12/2015

Non-Comparative, Multi-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in classical Hodgkin Lymphoma (cHL) Subjects after Failure of Autologous Stem Cell Transplant (ASCT)

Treatment

Leukemia
Lymphoma

VICCHEM1378

02/27/2015

A Phase 3 Study of IPI-145 versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Treatment

Hematologic

VICCBMT1456

12/23/2014

Allogeneic Stem Cell Transplantation of NiCord?, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescent and Adult Patients with Hematological Malignancies

Treatment

Lymphoma

VICCHEM1384

12/18/2014

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Treatment

Lymphoma

VICCHEM1463

11/18/2014

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects with Previously Treated Waldenstrom's Macroglobulinemia

Treatment

Myelodysplastic Syndrome

VICCHEM1487

11/10/2014

A Phase 1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS)

Treatment

Leukemia

VICCHEM1432

09/19/2014

A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients ≥ 60 Years Old with Relapsed/Refractory Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy and/or Transplantation

Treatment

Lymphoma

VICCHEM1402

09/15/2014

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Treatment

Multiple Myeloma

VICCHEM1448

09/09/2014

A Multicenter Phase 1/2b Study of the Bruton's Tyrosine Kinase Inhibitor, Ibrutinib (PCI-32765), in Combination with Carfilzomib (Kyprolis TM) in Subjects with Relapsed or Relapsed and Refractory Multiple Myeloma

Treatment

Leukemia

VICCHEM1423

08/08/2014

A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation

Treatment

Leukemia

VICCHEM13110

04/11/2014

A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Treatment

Lymphoma

VICCHEM13105

04/09/2014

A Single-Arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Follicular Lymphoma (FL)

Treatment

Hematologic

VICCHEM1274

03/31/2014

A Phase 3 Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physicians Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

Treatment

Leukemia
Lymphoma
Multiple Myeloma

VICCHEM1392

03/12/2014

A Phase 1, Open-label, Dose-Escalation Study of the Safety of SNX-5422 Mesylate in Subjects with Refractory Hematological Malignancies

Treatment

Hematologic
Leukemia

VICCHEM1346

01/21/2014

A Phase II, Randomized, Comparative Trial of Standard of Care, with or without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia

Treatment

Lymphoma

VICCHEM12103

12/31/2013

Multi-center Phase II Study to Establish Gene Expression Models Predicting Survival of Diffuse Large B-Cell Lymphoma Patients Treated With R-Chop

Treatment

Leukemia
Lymphoma
Pediatric Leukemia
Pediatric Lymphoma

VICCPED1338

06/27/2013

T2009-012 - A Phase I Dose Finding Study of Panobinostat in Children with Refractory Hematologic Malignancies

Treatment

Lymphoma

VICCHEM1284

06/05/2013

Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW 0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma

Treatment

Leukemia

VICCHEM1294

02/25/2013

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Complete Remission

Treatment

Lymphoma

VICCHEM1146

08/14/2012

Ofatumumab in combination with high dose cytarabine chemoimmunotherapy for patients with newly diagnosed Mantle Cell Lymphoma

Treatment

Adrenocortical
Bladder
Breast
Cervical
Colon
Dermatologic
Esophageal
GIST
Gastric/Gastroesophageal
Gynecologic
Head/Neck
Kidney (Renal Cell)
Liver
Lung
Multiple Myeloma
Neuroendocrine
Non Small Cell
Ovarian
Pancreatic
Prostate
Rectal
Sarcoma
Uterine

VICCMD1188

06/08/2012

An Open-Label, Phase II Study of Vemurafenib in Patients with BRAF V600 Mutation-Positive Cancers

Treatment

Leukemia
Pediatric Leukemia

COGAALL1131

04/05/2012

A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND #73789, NSC# 606869) in the Very High Risk Stratum

Treatment

Hematologic

VICCBMT1158

10/20/2011

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and other Indications

Treatment

Leukemia
Lymphoma
Multiple Myeloma

VICCPHI1044

01/24/2011

A Phase 1/2 Dose Escalation Safety, Pharmacokinetic and Efficacy Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 In Patients with Selected CD38+ Hematological Malignancies